OMIC Singular Genomics Corp: Market Capitalization to Book Value Ratio

Official company branding of Singular Genomics Systems Inc (OMIC)

The relative capitalization metric of Singular Genomics Systems (OMIC) demonstrates a balance between market expectations and tangible assets, where the value of 0.41 reflects current dynamics. Singular Genomics Systems lost its leadership to corporate behemoths after ceasing mass equipment sales. The business relied on a "razor-and-blade" model, creating customer dependency on consumables. Limited pricing power forced the company to offer budget solutions within narrow niches.

Singular Genomics Corp (OMIC): Capitalization to Book Value Ratio from 07/04/2022 to 03/01/2025
Manufactured products of Singular Genomics Systems, Inc.

This indicator is calculated as the ratio of the total market capitalization of all shares to the company's net equity. It determines the extent to which investors are overpaying relative to the company's tangible assets. For Singular Genomics (OMIC), this gap reflects market expectations for the development of the G4 sequencing ecosystem. The ratio of the company's estimated value to its book value visualizes the premium for technological leadership. Analyzing this curve helps avoid purchasing overvalued assets.

Competitor analysis

TEM (Tempus Labs) - Market Capitalization to Book Value Ratio|qiagen.com (QGEN) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Ionis (IONS)|Capitalization to Book Value Ratio RGEN|Market Value to Book Value Ratio Avidity RNA|Capitalization to Book Value Ratio CRISPR (CRSP)|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|ultragenyx.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio BEAM (Beam Therapeutics)|SRPT - Market Capitalization to Book Value|Twist Bio - Market Capitalization to Book Value Ratio|TXG (10x) - Market Capitalization to Book Value|Market Value to Book Value Ratio Intellia Therapeutics (NTLA)|Capitalization to Book Value Ratio stoketherapeutics.com|BLFS: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Wave Life Sciences Ltd WVE|Market Cap to Net Assets Ratio MAZE (Maze Tx)|Sionna Corp - Market Capitalization to Book Value Ratio|PRME - Market Value to Book Value Ratio|TSHA - Market Value to Book Value Ratio|QURE: Market Capitalization to Book Value Ratio|MGTX (MeiraGTx Holdings) - Market Capitalization to Book Value Ratio|RGNX - Market Value to Book Value Ratio|Market Value to Book Value Solid Corp (SLDB)|Ocugen, Inc. (OCGN) - Market Cap to Net Assets Ratio|Market Value to Book Value pacb.com (PACB)|BNTC (Benitec Biopharma) - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Design Therapeutics Inc DSGN|RCKT (Rocket Pharmaceuticals Inc) - Market Capitalization to Book Value Ratio|FDMT: Market-to-Book Ratio|Market Value to Book Value Ratio lexeotx.com|KRRO (Korro Bio) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio EDIT (Editas Medicine)|Market-to-Book Ratio SLN|Market Value to Book Value Ratio PRQR (ProQR Therapeutics N.V.)|Market Cap to Net Assets Ratio codexis.com (CDXS)|Market Capitalization to Book Value Ratio SGMO|Market Capitalization to Book Value Nautilus Biotechnology, Inc. NAUT|MGX: Market Capitalization to Book Value Ratio|DTIL: Market Cap to Net Assets Ratio|generationbio.com - Market Value to Book Value Ratio|Market Capitalization to Book Value Boundless Bio Inc|XCUR - Market Cap to Net Assets Ratio|Market Value to Book Value IMNN|PHIO (Phio Pharmaceuticals) - Market Value to Book Value Ratio|Market Capitalization to Book Value mustangbio.com MBIO|RNAZ: Market Cap to Net Assets Ratio|Bionano Genomics Inc. - Market-to-Book Ratio|Market Value to Book Value Ratio APDN (Applied DNA Sciences)|bluebirdbio.com (BLUE) - Market Capitalization to Book Value|IPA - Market Cap to Net Assets Ratio|Omega Therapeutics Inc (OMGA) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio RGLS (Regulus Therapeutics Inc)|Market-to-Book Ratio SYRS|Market Value to Book Value Ratio TBIO (Telesis Bio, Inc.)|Market Cap to Net Assets Ratio TCON (traconpharma.com)|Market Value to Book Value Ratio UBX